{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:51:38Z","timestamp":1780444298518,"version":"3.54.1"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T00:00:00Z","timestamp":1412294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Published evaluations of skin disease signs and health\u2010related quality of life (<jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL) upon therapy withdrawal and retreatment in psoriatic patients are limited to results of drug withdrawal after short\u2010term treatment. Analyses are lacking that evaluate patients' response to retreatment for patients treated successfully long\u2010term.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To study the efficacy and safety of adalimumab in patients with long\u2010term clinical responses to adalimumab who then discontinue therapy and are retreated with the same dosing regimen as the initial course. Skin disease signs and patients' <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL are evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This post hoc analysis of an open\u2010label study (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00195676) included patients who had responded favourably to adalimumab during initial treatment (\u226575% improvement in Psoriasis Area and Severity Index [<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 75 response]) and had maintained good clinical response for an extended period (up to 252\u00a0weeks); patients had Physician's Global Assessment (PGA) 0 or 1 before treatment interruption. Following drug withdrawal (up to 40\u00a0weeks), all patients were retreated with adalimumab 80\u00a0mg initial dose, followed by 40\u00a0mg every\u2010other\u2010week for 16\u00a0weeks. <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> response and <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 133 patients in this analysis, 24 (18%) relapsed during therapy withdrawal. After 16\u00a0weeks of retreatment, 75% who relapsed and 89.9% who did not relapse, had a <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 75 response; 89.5% achieved European Consensus Programme treatment goals after 16\u00a0weeks of retreatment. During drug withdrawal, <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL disproportionally worsened compared to skin disease signs; HROoL also considerably worsened for patients who did not relapse. Patients regained <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL upon retreatment with adalimumab. No new safety signals were identified in this study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Retreatment with adalimumab was successful in improving psoriasis skin signs and <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL in this subgroup with initial and extended responses to therapy followed by relapse after treatment withdrawal. Patient's <jats:styled-content style=\"fixed-case\">HRQ<\/jats:styled-content>oL should be considered, as it may substantially worsen during therapy interruption.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12677","type":"journal-article","created":{"date-parts":[[2014,10,4]],"date-time":"2014-10-04T02:39:30Z","timestamp":1412390370000},"page":"767-776","source":"Crossref","is-referenced-by-count":20,"title":["Adalimumab retreatment successfully restores clinical response and health\u2010related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption"],"prefix":"10.1111","volume":"29","author":[{"given":"K.B.","family":"Gordon","sequence":"first","affiliation":[{"name":"Feinberg School of Medicine Northwestern University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Tufts Medical Centre Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Langely","sequence":"additional","affiliation":[{"name":"Dalhousie University Halifax NS Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"van de Kerkhof","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.T.","family":"Belasco","sequence":"additional","affiliation":[{"name":"West Dermatology Redlands CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sundaram","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Okun","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Serra","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092767"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.022"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701646172"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08236.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10139.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500472838"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000250839"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04515.x"},{"key":"e_1_2_6_11_1","unstructured":"Humira[package insert].Abbott Laboratories North Chicago IL 2008."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/381905"},{"issue":"2","key":"e_1_2_6_17_1","first-page":"81","article-title":"The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis","volume":"35","author":"Palijan TZ","year":"2011","journal-title":"Coll Antropol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03537.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2006.12.032"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-014-0043-4"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12677","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12677","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.12677","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12677","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:24:07Z","timestamp":1695471847000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,3]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/jdv.12677"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12677","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,3]]}}}